Blog
Testosterone & Anti-Aging Therapy
Sterile & Non-Sterile Compounding
Clinical Laboratory Analysis
Dietary Supplements & Nutraceuticals
Consulting Services
Anti-Aging News
Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
The much anticipated announcement of the Third Temporary Extension of COVID-19 Telemedicine Flexibilities for...
Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
The much anticipated announcement of the Third Temporary Extension of COVID-19 Telemedicine...
Novo Nordisk asks the FDA to add Semaglutide to the Demonstrably Difficult to Compound list.
On October 22, 2024, Novo Nordisk asked the FDA to add semaglutide to the demonstrably difficult...
Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications
The much anticipated announcement of the Third Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications effective 15 November 2024. When Covid began the DEA needed to find a solution to allow patients access to care...
Novo Nordisk asks the FDA to add Semaglutide to the Demonstrably Difficult to Compound list.
On October 22, 2024, Novo Nordisk asked the FDA to add semaglutide to the demonstrably difficult to compound list. The Food and Drug Administration is proposing to establish criteria for the lists of drug products or categories of drug products that present...
FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of some of these peptides.
The FDA stirred enormous controversy when, without much notice, they placed some of the most popular peptides on their category 2 list, which disallows the compounding with these bulk substances also known as (APIs) Active Pharmaceutical Ingredients. Many of the...